Nuvation Bio Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Nuvation Bio reported Q2 2026 revenue of $31.7M ($23.2M from IBTROZI product sales, 25% QoQ growth; $8.5M from collaboration revenue). IBTROZI achieved market-leading position in ROS1+ NSCLC with ~85% of ~160 new patient starts in TKI-naïve setting (30% QoQ growth). Safusidenib Phase 2 data showed 51.9% ORR and 79.1% 36-month PFS in IDH1-mutant glioma; company initiated Phase 3 study (G307) outside U.S. and Phase 2 post-vorasidenib study (G209). Balance sheet: $661.0M cash/securities (June 30), plus $36.5M from July convertible notes overallotment. Net loss Q2: $62.8M (vs. $59.0M prior year).
Why this rating
IBTROZI market leadership and safusidenib pipeline expansion are meaningful commercial/clinical wins for a $497M-cap biotech, but company remains pre-profitability with large R&D/SG&A burn and net losses. Revenue still modest relative to costs. Moderate significance: real progress but not transformational yet.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.